Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;1(2):77-80.
doi: 10.4103/2279-042X.108375.

The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: A pilot study

Farahnaz Fatemi Naini  1 , Alireza Vaez Shooshtari  2 , Bahareh Ebrahimi  3 , Razieh Molaei  4
Affiliations

The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: A pilot study

Farahnaz Fatemi Naini et al. J Res Pharm Pract. 2012 Oct.

Abstract

Objective: Pseudocatalase/superoxide dismutase (PSD) is a topical gel considered having therapeutic effects in vitiligo. This study was designed to evaluate the efficacy of this combination in vitiligo.

Methods: This was a pilot randomized, double-blind, placebo-controlled trial on 46 symmetrical vitiligo lesions of limbs in 23 patients referring to dermatology clinics, Isfahan, Iran in 2010. Patients were received this formula or placebo gels for the right and left lesions. Lesion area and degree of pigmentation were assessed at baseline, 2, 4, and 6 months.

Findings: There were no significant changes in lesion area and perifollicular pigmentation in each group (P > 0.05).

Conclusion: The results indicated no significant therapeutic effect for PSD in vitiligo.

Keywords: Pseudocatalase/superoxide dismutase; efficacy; vitiligo.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Changes of the extent of vitiligo lesions’ area during the study in two groups, PSD: Pseudocatalase/superoxide dismutase
See this image and copyright information in PMC

References

    1. Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2009;360:160–9. - PubMed
    1. Miniati A, Weng Z, Zhang B, Stratigos AJ, Nicolaidou E, Theoharides TC. Neuro-immuno-endocrine processes in vitiligo pathogenesis. Int J Immunopathol Pharmacol. 2012;25:1–7. - PubMed
    1. Patel NS, Paghdal KV, Cohen GF. Advanced treatment modalities for vitiligo. Dermatol Surg. 2012;38:381–91. - PubMed
    1. Colucci R, Lotti T, Moretti S. Vitiligo: An update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2012;13:1885–99. - PubMed
    1. Hazneci E, Karabulut AB, Oztürk C, Batçioğlu K, Doğan G, Karaca S, et al. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int J Dermatol. 2005;44:636–40. - PubMed